- Home
- FHN vs QGEN Comparison
FHN vs QGEN Comparison
Compare FHN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHN | QGEN |
|---|---|---|
| Founded | 1864 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | 5700 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | FHN | QGEN |
|---|---|---|
| Price | $22.86 | $47.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | $24.05 | ★ $50.68 |
| AVG Volume (30 Days) | ★ 5.7M | 1.2M |
| Earning Date | 01-15-2026 | 11-04-2025 |
| Dividend Yield | 2.64% | ★ 3.21% |
| EPS Growth | 20.88 | ★ 331.20 |
| EPS | 1.65 | ★ 1.84 |
| Revenue | ★ $3,184,000,000.00 | $2,070,781,000.00 |
| Revenue This Year | $12.70 | $7.12 |
| Revenue Next Year | $2.54 | $6.13 |
| P/E Ratio | ★ $13.75 | $25.56 |
| Revenue Growth | 3.68 | ★ 5.32 |
| 52 Week Low | $15.19 | $37.63 |
| 52 Week High | $23.70 | $51.88 |
Technical Indicators
Market Signals| Indicator | FHN | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 55.46 |
| Support Level | $22.26 | $46.39 |
| Resistance Level | $22.98 | $48.13 |
| Average True Range (ATR) | 0.50 | 0.67 |
| MACD | 0.15 | 0.18 |
| Stochastic Oscillator | 91.86 | 68.53 |
Price Performance
Historical ComparisonAbout FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).